Literature DB >> 22409559

Central serous chorioretinopathy, corticosteroids, and uveitis.

Moncef Khairallah1, Rim Kahloun, Ilknur Tugal-Tutkun.   

Abstract

Any patient with a diagnosis of central serous chorioretinopathy (CSCR) should be questioned to determine any recent corticosteroid use, as the poor visual outcome may be due to unrecognized corticosteroid use. Atypical forms of CSCR may be misdiagnosed as an inflammatory serous retinal detachment, mainly Vogt-Koyanagi-Harada disease. CSCR that develops in association with preexisting uveitis could be a challenging diagnosis as it might be misinterpreted as a worsening of the primary inflammatory condition. Failure to differentiate CSCR from retinal or choroidal inflammatory diseases may result in inappropriate use of corticosteroids, leading to exacerbation of the condition and permanent visual loss. Discontinuation of corticosteroids should be the first step in the treatment of CSCR associated with corticosteroid therapy, and the use of immunosuppressive or immunomodulatory drugs may be required to control systemic or ocular inflammatory disease. The prognosis is usually favorable, but persistent visual loss may occur.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409559     DOI: 10.3109/09273948.2011.650776

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  12 in total

1.  Navigated laser photocoagulation in patients with non-resolving and chronic central serous chorioretinopathy.

Authors:  Bert Müller; Janina Tatsios; Jan Klonner; Daniel Pilger; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-06       Impact factor: 3.117

2.  Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet's Uveitis

Authors:  Hüseyin Baran Özdemir; Nazgül Zhoroeva; Pınar Çakar Özdal; Şengül Özdek
Journal:  Turk J Ophthalmol       Date:  2022-04-28

3.  Combined choroidal neovascularization and hypopituitarism in a patient with homozygous mutation in methylenetetrahydrofolate reductase gene.

Authors:  Aydogan Aydogdu; Cem Haymana; Kamil Baskoy; Ali H Durukan; Gokhan Ozgur; Omer Azal
Journal:  J Res Med Sci       Date:  2014-01       Impact factor: 1.852

4.  Multimodal imaging for the diagnosis of an atypical case of central serous chorioretinopathy.

Authors:  Rim Kahloun; Amel Chebbi; Sofiene Ben Amor; Imen Ksiaa; Leila Nacef; Moncef Khairallah
Journal:  Middle East Afr J Ophthalmol       Date:  2014 Oct-Dec

5.  Atypical Central Serous Chorioretinopathy.

Authors:  Zafer Cebeci; Merih Oray; Şerife Bayraktar; İlknur Tuğal-Tutkun; Nur Kır
Journal:  Turk J Ophthalmol       Date:  2017-08-15

6.  Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy.

Authors:  Ender Sirakaya; Zeynep Duru; Bekir Kuçuk; Necati Duru
Journal:  Indian J Ophthalmol       Date:  2020-05       Impact factor: 1.848

7.  Central serous chorioretinopathy and systemic corticosteroids in rheumatic diseases: report of three cases.

Authors:  Elia Valls Pascual; Lucía Martínez-Costa; Fernando Santander
Journal:  BMC Musculoskelet Disord       Date:  2015-12-05       Impact factor: 2.362

8.  Central Serous Chorioretinopathy Misdiagnosed as Posterior Uveitis and the Vicious Circle of Corticosteroid Therapy.

Authors:  Marina Papadia; Bruno Jeannin; Carl P Herbort
Journal:  J Ophthalmic Vis Res       Date:  2015 Jul-Sep

9.  Retinal and choroidal changes in steroid-associated central serous chorioretinopathy.

Authors:  Vikas Ambiya; Abhilash Goud; Mohammed Abdul Rasheed; Sankeert Gangakhedkar; Kiran Kumar Vupparaboina; Jay Chhablani
Journal:  Int J Retina Vitreous       Date:  2018-04-02

10.  Clinical profile of uveitis patients developing central serous chorioretinopathy: An experience at a tertiary eye care center in India.

Authors:  Parthopratim Dutta Majumder; Nitin Menia; Sridharan Sudharshan; Chetan Rao; Sudha K Ganesh; Jyotirmay Biswas
Journal:  Indian J Ophthalmol       Date:  2019-02       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.